

Logo of the Hospital/Laboratory

ERIC logo can be included if the laboratory has passed the ERIC TP53 Certification

## Mutational analysis of the TP53 gene

### Performed by

Laboratory  
Address

### Requested by

Hospital, Department...  
Address

Patient name:

Diagnosis: CLL

Type of material: *Peripheral blood/Genomic DNA*

Date of sample collection:

Date of sample delivery:

Result issued:

**Analytical method:** method, exons analyzed; for NGS - amplicon/capture based, library preparation

**Coverage:** for NGS only, minimum..., mean (median)... per base

**Detection limit:** e.g. 10-20% variant allele frequency

**Reference sequences:** LRG\_321t1, LRG\_321p1. Mutation nomenclature follows the Human Genome Variation Society (HGVS) guidelines.

**Result:** e.g. **MUTATION(S) DETECTED/ NO MUTATION DETECTED/ Low variant allele frequency mutation detected/ Variant with unknown clinical significance detected**

**Number of mutations:** ...

**Mutation description:** mutation name according the HGVS nomenclature (e.g.: *c.743G>A (p.R248Q)*)

**Mutation type:** missense/truncating... (e.g. *Missense variant in exon 7 within the DNA coding domain. According to the locus specific databases (IARC, TP53 website), this is a pathogenic hot-spot variant frequently found as somatic in human cancer.*)

**Allelic proportion:** ... % variant allele frequency

**Comparison with a previous sample (optional):** In case TP53 analysis is repeated over time, include a comment indicating change in mutation load/status. (e.g. *We observed an increase in variant allele frequency compared to previous sample - sampling date DD.MM.YYYY, variant allele frequency 13%.*)

Neutral polymorphism and benign variants are not included in this report and can be provided upon request.

**Interpretation/Conclusion:** Clinical consequence of the variant and summary of the finding in the context of the current knowledge \* (e.g. *A pathogenic variant was found within the TP53 gene. TP53 mutations are associated with adverse prognosis and poor response to chemo(immuno)therapy.*)

**Authorized signatures:**

Analysis performed by:

Result issued by:

---

\* For details on reporting, check ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia - update on methodological approaches and results interpretation (Malcikova et al., *Leukemia* 2018). Examples of report forms are included as Supplementary Information.